TABLE 4.
Base-case results (lifetime horizon#), intent to treat population
| FF/UMEC/VI | BUD/FOR | Incremental | |
| Outcomes | |||
| Predicted cumulative exacerbations | |||
| Moderate exacerbations | 5.793 | 5.804 | –0.011 |
| Severe exacerbations | 1.422 | 1.434 | –0.012 |
| Any moderate and/or severe exacerbation | 7.216 | 7.238 | –0.023 |
| Total LYs (discounted) | 9.094 | 8.561 | 0.533 |
| Total QALYs (discounted) | 6.638 | 6.132 | 0.506 |
| Costs | |||
| Maintenance | £7531 | £8495 | –£965 |
| Moderate exacerbation | £2459 | £2484 | –£25 |
| Severe exacerbation | £6874 | £6974 | –£100 |
| Pneumonia | £4261 | £3927 | £334 |
| Treatment | £4887 | £3339 | £1549 |
| Discontinuation | £404 | £641 | –£237 |
| Total costs | £26 416 | £25 860 | £556 |
| ICER per LY | £1042 | Referent | |
| ICER per QALY | £1098 | Referent | |
FF: fluticasone furoate; UMEC: umeclidinium; VI: vilanterol; BUD: budesonide; FOR: formoterol; LY: life year; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio. #: Outcomes and costs observed over the complete period (trial-based and Markov models).